Cyclic Adenosine Monophosphates for Reducing the Formation of Adhesions
University of Pittsburgh
posted on 07/06/2009
This invention involves compositions and methods for reducing the formation of adhesions by the administration of cyclic adenosine monophosphates.
Suggested Uses
- Local application in the tissue field where adhesion formation or injury may occur, will occur or has occurred
- Systemic administration before tissue injury, during tissue injury or after tissue injury.
Advantages
- Safety: In contrast to adhesion barriers, the invention would not involve placing a foreign body in the surgical cavity. Present adhesion barriers can cause immunological reactions. Also, the cyclic adenosine monophosphates are naturally-occuring substances and therefore should be quite safe.
- Convenience: The cyclic adenosine monophosphates can be quickly and easily administered with a syringe.
- Can be used in minimally-invasive surgery: This is an extremely important point because adhesion barriers are not approved for this applicaiton and minimally-invasive surgery is the future of surgery.
- Pharmaceutical characteristics: The cyclic adenosine monophosphates are highly stable and highly soluble in aqueous solutions.
- Unlike present adhesion barriers, the invention should be effective even if blood is in the surgical field.
- It is likely that the invention will be more efficacious than existing adhesion barriers.
- It is likely that the invention would speed tissue healing.
File Number: 1815
Other Information:
BACKGROUND
Adhesions are fibrous bands that form between tissues and organs as a result of an injury. Thus, adhesions are essentially internal scar tissue and occur naturally as a part of the body’s healing processes. Unfortunately, adhesions can prevent tissues and organs from moving freely thus sometimes causing organs and tissues to become twisted or pulled from their normal positions. This results in pain and dysfunction and at times can be life-threatening.
This innovation currently is not available for online licensing. Please contact Alexander Ducruet at University of Pittsburgh for more information.
Find more innovations
